Physician profile
Katie S Schroeder
NPI 1487818001
$729,532.91
in general payments reported to CMS, 2019-2025
32 companies · $197K in 2025
The $197K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89K · 2020: $46K · 2021: $35K · 2022: $83K · 2023: $119K · 2024: $160K · 2025: $197K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $394K · Travel and Lodging: $51K · Consulting Fee: $18K · Food and Beverage: $13K · Education: $13.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $394,315.86 |
| Travel and Lodging | $50,993.65 |
| Consulting Fee | $17,632.50 |
| Food and Beverage | $12,825.34 |
| Education | $13.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $390,839.95 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| E.R. Squibb & Sons, L.L.C. | $114,252.82 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $78,931.12 | 2020-2025 | Tremfya, Stelara, Remicade |
| Janssen Scientific Affairs, LLC | $75,922.88 | 2019-2022 | |
| Pfizer INC. | $33,728.23 | 2019-2025 | |
| Lilly USA, LLC | $30,734.46 | 2023-2025 | Omvoh |
| Celgene Corporation | $2,462.09 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $864.69 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $265.77 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $182.23 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.84 | 2022-2025 | Xifaxan, Trulance |
| Zimmer Biomet Holdings, INC. | $145.66 | 2024 | Sternalock Blu System |
| Fresenius Kabi USA, LLC | $117.76 | 2023-2024 | Idacio, Smoflipid |
| Aimmune Therapeutics, INC. | $115.20 | 2024-2025 | Vowst |
| Organon LLC | $100.15 | 2024-2025 | Hadlima, Renflexis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $92.58 | 2024-2025 | Vegzelma, Zymfentra |
| Amgen INC. | $82.42 | 2022-2023 | Avsola, Amjevita |
| Ardelyx, INC. | $69.38 | 2022-2024 | Ibsrela |
| Capsovision, INC. | $57.61 | 2024-2025 | Capsocam Plus |
| Ferring Pharmaceuticals INC. | $56.21 | 2022-2024 | Rebyota, Clenpiq |
| Allergan, INC. | $44.27 | 2019 | |
| Redhill Biopharma INC. | $39.66 | 2023 | Movantik, Talicia, Aemcolo |
| Merck Sharp & Dohme LLC | $39.13 | 2021-2022 | |
| Novo Nordisk INC | $35.70 | 2022 | |
| Ambu INC. | $33.32 | 2024 | |
| Ucb, INC. | $30.17 | 2024 | Cimzia |
| Madrigal Pharmaceuticals | $22.70 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $21.64 | 2025 | |
| Qol Medical, LLC | $21.62 | 2022 | |
| Conmed Corporation | $21.33 | 2019 | |
| Dynavax Technologies Corporation | $20.32 | 2025 | Heplisav-B |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.